Skip Navigation


European Heart Journal Advance Access originally published online on January 9, 2009
European Heart Journal 2009 30(5):540-548; doi:10.1093/eurheartj/ehn571
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
30/5/540    most recent
ehn571v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tardif, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tardif, J.-C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial

Jean-Claude Tardif1,*, Piotr Ponikowski2,3, Thomas Kahan4 for the ASSOCIATE study Investigators

1 Montreal Heart Institute, Université de Montreal, 5000 Belanger Street, Montreal, Quebec, Canada H1T 1C8
2 Clinical Military Hospital, Wroclaw, Poland
3 Wroclaw Medical University (2nd Cardiology Department), Wroclaw, Poland
4 Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden

Received 25 July 2008; revised 18 November 2008; accepted 27 November 2008; online publish-ahead-of-print 9 January 2009.

* Corresponding author. Tel: +1 514 376 3330 ext. 3564, Fax: +1 514 376 1355, Email: jean-claude.tardif{at}icm-mhi.org

See page 524 for the editorial comment on this article (doi:10.1093/eurheartj/ehp027)

Aims: To evaluate the anti-anginal and anti-ischaemic efficacy of the selective If current inhibitor ivabradine in patients with chronic stable angina pectoris receiving beta-blocker therapy.

Methods and results: In this double-blinded trial, 889 patients with stable angina receiving atenolol 50 mg/day were randomized to receive ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months, or placebo. Patients underwent treadmill exercise tests at the trough of drug activity using the standard Bruce protocol for randomization and at 2 and 4 months. Total exercise duration at 4 months increased by 24.3 ± 65.3 s in the ivabradine group, compared with 7.7 ± 63.8 s with placebo (P < 0.001). Ivabradine was superior to placebo for all exercise test criteria at 4 months (P < 0.001 for all) and 2 months (P-values between <0.001 and 0.018). Ivabradine in combination with atenolol was well tolerated. Only 1.1% of patients withdrew owing to sinus bradycardia in the ivabradine group.

Conclusion: The combination of ivabradine 7.5 mg b.i.d. and atenolol at the commonly used dosage in clinical practice in patients with chronic stable angina pectoris produced additional efficacy with no untoward effect on safety or tolerability.

Key Words: Ivabradine • Myocardial ischaemia • Stable angina pectoris • Heart rate • If inhibition • Combination therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

A new combination therapy in stable angina pectoris
Ahmad Sajadieh
EHJ 2009 30: 524-525. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
K. Swedberg, M. Komajda, M. Bohm, J. S. Borer, I. Ford, and L. Tavazzi
Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT)
Eur J Heart Fail, January 1, 2010; 12(1): 75 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
K. Fox, I. Ford, Ph. G. Steg, M. Tendera, M. Robertson, R. Ferrari, and on behalf of the BEAUTIFUL Investigators
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
Eur. Heart J., October 1, 2009; 30(19): 2337 - 2345.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
R. Ferrari
A step further with ivabradine: SIGNIfY (Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease)
Eur. Heart J. Suppl., August 1, 2009; 11(suppl_D): D19 - D27.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
J.-C. Tardif
Heart rate as a treatable cardiovascular risk factor
Br. Med. Bull., June 1, 2009; 90(1): 71 - 84.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. Sajadieh
A new combination therapy in stable angina pectoris
Eur. Heart J., March 1, 2009; 30(5): 524 - 525.
[Full Text] [PDF]

Home page
 ESC Textbook of Cardiovascular MedicineHome page
F. Crea, P. G. Camici, R. De Caterina, and G. A. Lanza
CHAPTER 17 Chronic Ischaemic Heart Disease
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.